<DOC>
	<DOC>NCT02176850</DOC>
	<brief_summary>This post-marketing surveillance study was designed to supplement under conditions of normal clinical practice the data on the safety, tolerability and efficacy of Micardis® collected during the clinical studies.</brief_summary>
	<brief_title>Safety, Tolerability and Efficacy of Micardis® in Patients With Essential Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Telmisartan</mesh_term>
	<criteria>Patients of both sexes with essential hypertension and a minimum age of 18 years (Not applicable)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>